PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29209219-0	2017	Differential Effects of Inhibitor Combinations on Lysophosphatidic Acid-Mediated Chemokine Secretion in Unprimed and Tumor Necrosis Factor-alpha-Primed Synovial Fibroblasts.	lysophosphatidic acid	50-71	tumor necrosis factor	Homo sapiens	117-144	
29209219-4	2017	RAFLS pretreated or not with TNFalpha were stimulated with LPA.	lysophosphatidic acid	59-62	tumor necrosis factor	Homo sapiens	29-37	
29209219-8	2017	Priming with TNFalpha enhanced LPA-mediated MSK phosphorylation and cytokine/chemokine production.	lysophosphatidic acid	31-34	tumor necrosis factor	Homo sapiens	13-21	
29209219-12	2017	In TNFalpha-primed RAFLS the super-production of IL-8 and IL-6 induced by LPA occurs mainly via MSK-independent pathways, and simultaneous inhibition of at least two MAPK signaling pathways was required to block their synthesis.	lysophosphatidic acid	74-77	tumor necrosis factor	Homo sapiens	3-11	
29209219-13	2017	Since simultaneous inhibition of both the p38MAPK and ERK-MSK-CREB pathways are required to significantly reduce LPA-mediated IL-8 and IL-6 production in TNFalpha-preconditioned RAFLS, drug combinations targeting these two pathways are potential new strategies to treat rheumatoid arthritis.	lysophosphatidic acid	113-116	tumor necrosis factor	Homo sapiens	154-162